Status:
COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study
Lead Sponsor:
Institut Bergonié
Collaborating Sponsors:
Bayer
Conditions:
Metastatic Solid Tumors
Eligibility:
All Genders
1-100 years
Brief Summary
This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis.
Detailed Description
This retrospective study has a primary objective to estimate the incidence of NTRK gene fusion depending on the histological diagnosis. The tropomyosin receptor kinase (Trk) receptor family comprises ...
Eligibility Criteria
Inclusion
- Age ≥ 1 month.
- Subject has/had a histologically or cytologically confirmed diagnosis of solid tumor including but not exclusively: soft tissue sarcoma, BRAF wild type melanoma, KRAS wild-type colorectal cancer, central nervous system, EGFR-wild type non-small cell lung cancer.
- Subject has locally advanced/unresectable or metastatic disease.
- Subject has received at least one systemic anti-cancer therapy for locally advanced/unresectable or metastatic disease for which there is available outcome information in terms of PFS, or the latter can be estimated based on the subject's records.
- Subject has tumor material available for immunoscreening (IHC for NTRK gene fusions).
- Written and voluntary informed consent understood, signed and dated, or a waiver of consent is granted according to French régulations.
Exclusion
- • Subjects who have not yet received or completed at least one systemic anti-cancer therapy for locally advanced/unresectable or metastatic cancer.
Key Trial Info
Start Date :
December 23 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
3820 Patients enrolled
Trial Details
Trial ID
NCT04010240
Start Date
December 23 2015
End Date
December 31 2022
Last Update
October 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Bergonié
Bordeaux, Aquitaine, France, 33000